Systemic infections in multiple sclerosis and experimental autoimmune encephalomyelitis

Archives of Physiology and Biochemistry

Volumn 113, Issue 3, 2007, Pages 124-130

  Tauber, Simone C ^a   Nau, Roland ^a   Gerber, Joachim ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Bacterial infection; Experimental autoimmune encephalomyelitis; Microglia; Minocycline; Multiple sclerosis; Viral infection

Indexed keywords

ANTIINFECTIVE AGENT; ANTIVIRUS AGENT;

ALLERGIC ENCEPHALOMYELITIS; BACTERIAL INFECTION; CONFERENCE PAPER; HUMAN; MULTIPLE SCLEROSIS; VIRUS INFECTION;

ANTI-BACTERIAL AGENTS; ANTIVIRAL AGENTS; BACTERIAL INFECTIONS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; MULTIPLE SCLEROSIS; VIRUS DISEASES;

BACTERIA (MICROORGANISMS);

EID: 35148865167     PISSN: 13813455     EISSN: 17444160     Source Type: Journal    
DOI: 10.1080/13813450701531227     Document Type: Conference Paper

References (53)

1. Aasjord P, Nyland H. 1981. Antibodies to staphylococcal lipoteichoic acid in serum and in cerebrospinal fluid from patients with multiple sclerosis. Acta Pathol Microbiol Scand [C] 89:333-8.
2. Aasjord P, Nyland H, Haaheim LR. 1986. Intrathecal synthesis of antibodies to staphylococcal antigens in multiple sclerosis patients. Acta Pathol Microbiol Immunol Scand [C] 94:97-103.
3. Alvarez-Lafuente R, De las Heras V, Bartolome M, Picazo JJ, Arroyo R. 2004. Relapsing-remitting multiple sclerosis and human herpesvirus 6 active infection. Arch Neurol 61:1523-7.
4. Alvarez-Lafuente R, Fernandez-Gutierrez B, de Miguel S, Jover JA, Rollin R, Loza E, Clemente D, Lamas JR. 2005. Potential relationship between herpes viruses and rheumatoid arthritis: Analysis with quantitative real time polymerase chain reaction. Ann Rheum Dis 64:1357-9.
5. Andersen O, Lygner PE, Bergstrom T, Andersson M, Vahlne A. 1993. Viral infections trigger multiple sclerosis relapses: A prospective seroepidemiological study. J Neurol 240:417-22.
6. Balin BJ, Gerard HC, Arking EJ, Appelt DM, Branigan PJ, Abrams JT, Whittum-Hudson JA, Hudson AP. 1998. Identification and localization of Chlamydia pneumoniae in the Alzheimer's brain. Med Microbiol Immunol 187:23-42.
7. Banati RB, Newcombe J, Gunn RN, Cagnin A, Turkheimer F, Heppner F, Price G, Wegner F, Giovannoni G, Miller DH, et al. 2000. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: Quantitative in vivo imaging of microglia as a measure of disease activity. Brain 123:2321-37.
8. Brocke S, Gaur A, Piercy C, Gautam A, Gijbels K, Fathman CG, Steinman L. 1993. Induction of relapsing paralysis in experimental autoimmune encephalomyelitis by bacterial superantigen. Nature 365:642-4.
9. Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong VW. 2002. Targeting leukocyte MMPs and transmigration: Minocycline as a potential therapy for multiple sclerosis. Brain 125:1297-308.
10. Buljevac D, Flach HZ, Hop WC, Hijdra D, Laman JD, Savelkoul HF, van Der Meche FG, van Doom PA, Hintzen RQ. 2002. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 125:952-60.
11. Casserly G, Barry T, Tourtellotte WW, Hogan EL. 2007. Absence of Mycoplasma-specific DNA sequence in brain, blood and CSF of patients with multiple sclerosis (MS): A study by PCR and real-time PCR. J Neurol Sci 253:48-52.
12. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, et al. 2000. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 6:797-801.
13. Crisi GM, Santambrogio L, Hochwald GM, Smith SR, Carlino JA, Thorbecke GJ. 1995. Staphylococcal enterotoxin B and tumornecrosis factor-alpha-induced relapses of experimental allergic encephalomyelitis: Protection by transforming growth factor-beta and interleukin-10. Eur J Immunol 25:3035-40.
14. Cunningham C, Wilcockson DC, Campion S, Lunnon K, Perry VH. 2005. Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. J Neurosci 25:9275-84.
15. Derfuss T, Gurkov R, Then Bergh F, Goebels N, Hartmann M, Barz C, Wilske B, Autenrieth I, Wick M, Hohlfeld R, et al. 2001. Intrathecal antibody production against Chlamydia pneumoniae in multiple sclerosis is part of a polyspecific immune response. Brain 124:1325-35.
16. Du C, Yao SY, Ljunggren-Rose A, Sriram S. 2002. Chlamydia pneumoniae infection of the central nervous system worsens experimental allergic encephalitis. J Exp Med 196:1639-44.
17. Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, Triarhou LC, Chernet E, Perry KW, Nelson DL, et al. 2001. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA 98:14,669-74.
18. Edwards S, Zvartau M, Clarke H, Irving W, Blumhardt LD. 1998. Clinical relapses and disease activity on magnetic resonance imaging associated with viral upper respiratory tract infections in multiple sclerosis. J Neurol Neurosurg Psychiatry 64:736-41.
19. Fainardi E, Castellazzi M, Casetta I, Cultrera R, Vaghi L, Granieri E, Contini C. 2004. Intrathecal production of Chlamydia pneumoniae-specific high-affinity antibodies is significantly associated to a subset of multiple sclerosis patients with progressive forms. J Neurol Sci 217:181-8.
20. Felgenhauer K, Reiber H. 1992. The diagnostic significance of antibody specificity indices in multiple sclerosis and herpes virus induced diseases of the nervous system. Clin Investig 70:28-37.
21. Fleischer B, Schrezenmeier H. 1988. T cell stimulation by staphylococcal enterotoxins. Clonally variable response and requirement for major histocompatibility complex class II molecules on accessory or target cells. J Exp Med 167:1697-707.
22. Gaydos CA. 2001. Chlamydia pneumoniae and its proposed link to multiple sclerosis: to be or not to be? Neurology 56:1126-7.
23. Giuliani F, Fu SA, Metz LM, Yong VW. 2005a. Effective combination of minocycline and interferon-beta in a model of multiple sclerosis. J Neuroimmunol 165:83-91.
24. Giuliani F, Metz LM, Wilson T, Fan Y, Bar-Or A, Yong VW. 2005b. Additive effect of the combination of glatiramer acetate and minocycline in a model of MS. J Neuroimmunol 158: 213-221.
25. Herrmann I, Kellert M, Schmidt H, Mildner A, Hanisch UK, Bruck W, Prinz M, Nau R. 2006. Streptococcus pneumoniae infection aggravates experimental autoimmune encephalomyelitis via Toll-like receptor 2. Infect Immun 74:4841-8.
26. Herrmann I, Kellert M, Spreer A, Gerber J, Eiffert H, Prinz M, Nau R. 2007. Minocycline delays but does not attenuate the course of experimental autoimmune encephalomyelitis in Streptococcus pneumoniae-infected mice. J Antimicrob Chemother 59:74-9.
27. Hoijer MA, Melief MJ, Calafat J, Roos D, van den Beemd RW, van Dongen JJ, Hazenberg MP. 1997. Expression and intracellular localization of the human N-acetylmuramyl-L-alanine amidase, a bacterial cell wall-degrading enzyme. Blood 90:1246-54.
28. Johnson HM, Russell JK, Pontzer CH. 1991. Staphylococcal enterotoxin microbial superantigens. Faseb J 5:2706-12.
29. Kengatharan KM, De Kimpe S, Robson C, Foster SJ, Thiemermann C. 1998. Mechanism of Gram-positive shock: Identification of peptidoglycan and lipoteichoic acid moieties essential in the induction of nitric oxide synthase, shock, and multiple organ failure. J Exp Med 188:305-15.
30. Krametter D, Niederwieser G, Berghold A, Birnbaum G, StrasserFuchs S, Hartung HP, Archelos JJ. 2001. Chlamydia pneumoniae in multiple sclerosis: Humoral immune responses in serum and cerebrospinal fluid and correlation with disease activity marker. Mult Scler 7:13-18.
31. Kriesel JD, White A, Hayden FG, Spruance SL, Petajan J. 2004. Multiple sclerosis attacks are associated with picornavirus infections. Mult Scler 10:145-8.
32. Mayer AM. 1998. Therapeutic implications of microglia activation by lipopolysaccharide and reactive oxygen species generation in septic shock and central nervous system pathologies: A review. Medicina (B Aires) 58:377-85.
33. Munger KL, Peeling RW, Hernan MA, Chasan-Taber L, Olek MJ, Hankinson SE, Hunter D, Ascherio A. 2003. Infection with Chlamydia pneumoniae and risk of multiple sclerosis. Epidemiology 14:141-7.
34. Nessler S, Dodel R, Bittner A, Reuss S, Du Y, Hemmer B, Sommer N. 2002. Effect of minocycline in experimental autoimmune encephalomyelitis. Ann Neurol 52:689-90.
35. Nguyen MD, D'Aigle T, Gowing G, Julien JP, Rivest S. 2004. Exacerbation of motor neuron disease by chronic stimulation of innate immunity in a mouse model of amyotrophic lateral sclerosis. J Neurosci 24:1340-9.
36. Nimmerjahn A, Kirchhoff F, Helmchen F. 2005. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308:1314-18.
37. Panitch HS. 1994. Influence of infection on exacerbations of multiple sclerosis. Ann Neurol 36(Suppl):S25-28.
38. Perry VH, Newman TA, Cunningham C. 2003. The impact of systemic infection on the progression of neurodegenerative disease. Nat Rev Neurosci 4:103-12.
39. Popovic N, Schubart A, Goetz BD, Zhang SC, Linington C, Duncan ID. 2002. Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann Neurol 52:215-23.
40. Pugliatti M, Rosati G, Carton H, Riise T, Drulovic J, Vecsei L, Milanov I. 2006. The epidemiology of multiple sclerosis in Europe. Eur J Neurol 13:700-22.
41. Reiber H, Felgenhauer K. 1987. Protein transfer at the blood cerebrospinal fluid barrier and the quantitation of the humoral immune response within the central nervous system. Clin Chim Acta 163:319-28.
42. Reiber H, Lange P. 1991. Quantification of virus-specific antibodies in cerebrospinal fluid and serum: Sensitive and specific detection of antibody synthesis in brain. Clin Chem 37:1153-60.
43. Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, Jin L, Dykes Hoberg M, Vidensky S, Chung DS, et al. 2005. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433:73-7.
44. Schiffenbauer J, Johnson HM, Butfiloski EJ, Wegrzyn L, Soos JM. 1993. Staphylococcal enterotoxins can reactivate experimental allergic encephalomyelitis. Proc Natl Acad Sci USA 90:8543-6.
45. Schrijver IA, van Meurs M, Melief MJ, Wim Ang C, Buljevac D, Ravid R, Hazenberg MP, Laman JD. 2001. Bacterial peptidoglycan and immune reactivity in the central nervous system in multiple sclerosis. Brain 124:1544-54.
46. Sibley WA, Bamford CR, Clark K. 1985. Clinical viral infections and multiple sclerosis. Lancet 1:1313-15.
47. Sly LM, Krzesicki RF, Brashler JR, Buhl AE, McKinley DD, Carter DB, Chin JE. 2001. Endogenous brain cytokine mRNA and inflammatory responses to lipopolysaccharide are elevated in the Tg2576 transgenic mouse model of Alzheimer's disease. Brain Res Bull 56:581-8.
48. Stratton CW, Sriram S. 2003. Association of Chlamydia pneumoniae with central nervous system disease. Microbes Infect 5:1249-53.
49. Stuertz K, Schmidt H, Eiffert H, Schwartz P, Mader M, Nau R. 1998. Differential release of lipoteichoic and teichoic acids from Streptococcus pneumoniae as a result of exposure to beta-lactam antibiotics, rifamycins, trovafioxacin, and quinupristindalfopristin. Antimicrob Agents Chemother 42:277-81.
50. van Langevelde P, van Dissel JT, Ravensbergen E, Appelmelk BJ, Schrijver IA, Groeneveld PH. 1998. Antibiotic-induced release of lipoteichoic acid and peptidoglycan from Staphylococcus aureus: Quantitative measurements and biological reactivities. Antimicrob Agents Chemother 42: 3073-8.
51. Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan PH, Koistinaho J. 1999. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci USA 96:13,496-500.
52. Yucesan C, Sriram S. 2001. Chlamydia pneumoniae infection of the central nervous system. Curr Opin Neurol 14:355-9.
53. Yulug B, Kilic U, Kilic E, Bahr M. 2004. Rifampicin attenuates brain damage in focal ischemia. Brain Res 996:76-80.